ReNeuron Group (ReNeuron Group) Growth Rank : 0 (As of Apr. 30, 2024)

View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Growth Rank?

ReNeuron Group has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ReNeuron Group Growth Rank Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (ReNeuron Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

RENE.GB:UK RENE:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.